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Abstract
Purpose Unclear labeling has been recognized as an important cause of look-alike medication errors. Little is known about which
labeling practices are currently used in European hospitals. The aim of this article is to obtain an overview of the labeling
practices for parenteral medications, in relation to national guidelines, in the Netherlands, Germany, and the UK.
Methods An online survey was conducted using the Qualtrics® software. The survey was distributed to hospital pharmacists in
the Netherlands, Germany, and the UK. The results were downloaded fromQualtrics and exported toMicrosoft Excel. Data were
categorized into groups and analyzed descriptively.
Results In total, 104 responses were received. The response rate was 63% (n = 48) in the Netherlands and 11% (n = 41) for Germany;
for theUK, 15 responseswere received. In general almost 90%of the respondents followed theNational guidelines concerning labeling
of pharmacy-prepared parenteral products. The use of label enhancement techniqueswas relatively low in all countries. On average, the
use of “Tall Man” lettering was 19%, the use of color coding was 29%, and the use of a barcode on the label was 27%.
Conclusion Label-enhancement methods for parenteral medication in hospital pharmacies do not seem to be widely implemented and
acknowledged in European hospitals, but response rates were limited for two countries. Greater standardization in conjunction with
research for evidence-based enhancement techniques is needed to guide improvement in labeling practices across Europe.
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Introduction
Hospital pharmacists have an important role in promoting and
ensuring the safe use of medicines [1]. Good labeling of medi-
cation is recognized as an important aspect of medication safety
in hospitals, but 20%ormore ofmedication errorsmay be related
to confusing packaging and poor labeling [2, 3]. The basic
function of a medication label is to enable correct identification
and safe administration of the product. So-called look-alike la-
bels, because of similar drug names (e.g., dobutamine–dopa-
mine) or otherwise similar appearance of the labels, could result
in the administration of the wrong drug. In particular for paren-
teral medications, this can have serious consequences for patients
[4–6].Many parenteral medications involve high-riskmedication
with a narrow therapeutic range. Few studies have focused on
labeling issues in parenteral medication. In anesthesia,
Abeysekera et al. have shown that 20% of reported medication
errors involved labeling errors of syringes [7].
Enhancing the readability of labels could be done in differ-
ent ways [4, 5]. Closed loop systems using barcode technolo-
gies have been introduced in some hospitals [1, 8]. However,
medication labels need to still be easily readable for humans,
for example in emergency situations. “Tall Man” lettering is
regarded in the literature as a potential solution; this approach
aims to maximize the difference between two similar drug
names and avoid confusion by capitalizing part of the drug
names [9]. A recently published systematic review found ev-
idence from laboratory-based studies that “Tall Man” lettering
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contributes to reduced error rates, which the authors suggested
was due to a better readability of medication labels, but eval-
uations in real-life settings are needed to strengthen this con-
clusion [10]. Several national health organizations have en-
dorsed “Tall Man” lettering including the Joint Commission
International (JCI) and the Institute for Safe Medication
Practices (ISMP) in the USA [9, 11, 12]. The EMA guideline
incorporated the use of capital letters, but did not explicitly
mention Tall Man lettering and its purposed use for distinction
between words [6]. Elsewhere in anesthesia, color-coded la-
bels are used to distinguish between different substance clas-
ses. This approach is described in an international standard
(ISO 26825) [13], but a recent systematic review reported that
there is little published evidence supporting enhanced read-
ability by using color-coding [10].
Internationally, there is no consensus about the content and
form of parenteral medication labels. There is also a lack of
guidance from the FDA and European Medicines Agency
(EMA) [6, 11]. This concerns the labels produced by manu-
facturers as well as labels produced in the hospitals by the
hospital pharmacies or on the wards. As little is known about
which labeling practices are currently used in European hos-
pitals, a survey across countries may therefore be useful to
identify best practices and drive improvement [1].
Therefore, we conducted a survey among hospital pharma-
cists to obtain an overview of the labeling practices for paren-
teral medications, in relation to national guidelines, in the
Netherlands, Germany, and the UK.
Methods
An online survey using the Qualtrics® software was devel-
oped. The survey was divided into three parts; the first part
concerned the general information of the hospital pharmacy
(type, place, number of beds, etc.), the second asked partici-
pants to describe label-enhancement methods used for paren-
teral medication prepared by their hospital pharmacy, and the
final part consisted of questions about their hospitals’ labeling
policy for parenteral medication prepared and used on hospital
wards. The survey was distributed in the Netherlands,
Germany, and the UK. In the Netherlands, the survey was sent
to all heads of hospital pharmacies using a list of contact
details obtained from the Dutch Association of Hospital
Pharmacists. In Germany, the survey was distributed to all
hospital pharmacists based on the contact information of 392
German hospital pharmacies obtained through the
Bundesverband Deutscher Krankenhausapotheker (ADKA).
The UK survey was distributed by a contact at the UK
Pharmaceutical Aseptics Services Group (PASG) to the mem-
bers of the North West Aseptic Services Group (ASG) and the
wider PASG. The survey for the Netherlands was launched in
January 2016, for the UK and Germany in June 2017. The
questions in the survey included a mix of multiple choice and
open questions. After 2 weeks, a reminder was sent by email;
a second reminder (also by email) was sent another week later.
The results were downloaded from Qualtrics and exported to
Microsoft Excel. Data were categorized into groups and ana-
lyzed descriptively. Discrepancies or unclear answers were
verified with the respondent (n = 2).
Results
Overall, 104 responses were received where each response
represented an individual hospital. The response rate was
63% (n = 48) in the Netherlands and 11% (n = 41) for
Germany. A response rate could not be calculated for the
UK (15 respondents) as it was unknown how many hospital
pharmacists received the survey. From the respondents, re-
spectively, 31, 36, and 15 hospitals have a production facility
in the pharmacy and were taken into further analysis. Most
respondents reported that their hospital pharmacies followed
relevant national guidelines concerning labeling of pharmacy-
prepared parenteral products, with 84, 92, and 95% in agree-
ment respectively for the Netherlands, Germany, and the UK.
The use of label-enhancement methods used by pharmacies
varied between the countries. The use of “Tall Man” lettering
was relatively low in all countries, respectively five (5/ 31,
16.1%), five (5/ 36, 13.9%), and four (4/15, 26.4%) for par-
enteral medications in the Netherlands, Germany, and the UK.
In Germany, half (50%) of the respondents used color cod-
ing, while only 16% and 20% of the respondents used this
strategy respectively in the Netherlands and the UK. Of the
pharmacies in Germany using color coding, six (6/18, 33.3%)
used color coding according to the ISO 26825, two (2/18,
11.1%) used the ISO 26825 partially but combined this with
their own color coding, and ten (10/18 55.6%) did not follow
the ISO 26825 but used their own coloring system to differ-
entiate between specific drugs. Some pharmacies used a com-
bination of color with another enhancement technique, e.g., in
Germany, one pharmacy (1/18) used color coding in combi-
nation with a barcode, and four pharmacies (4/18) used color
in combination with “Tall Man” lettering.
A total of 55% (n = 17/31) of the respondents with a pro-
duction facility in the Netherlands used a barcode or data
matrix code on the label and these were 6% and 20% in
Germany and the UK (see Table 1 for all results).
Discussion
This is the first study to explore the labeling practices for
parenteral medications in European hospital, and the results
provide important insight concerning the use of methods of
label enhancement of parenteral medications in hospital
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pharmacies. Label-enhancement methods were not widely
used in the Netherlands, Germany, or the UK, with differences
between the countries in approaches they did employ. While
in Germany, color coding was the most commonly used meth-
od, in the Netherlands, this was the barcode/data matrix code
method. Figure 1 shows examples of labels using Tall Man
lettering, barcode, and data matrix beside the ISO26825; in
Germany, they also used theDIVI system; a color-coding system
developed by the Deutsche Interdisziplinäre Vereinigung für
Intensiv-und Notfallmedizin for labeling on the ward. Figure 2
shows an overview of the DIVI color scheme [14, 15]. In the
guideline of the UK, color is mentioned as an option to enhance
labels, but no reference to the ISO 26825 guidance is included
[16]. In the Dutch labeling guideline, no conclusive advice is
provided about the use of color on labels [17]. Every hospital
can decidewhether or not to use color on labels, and those that do
are free to use their own color system instead of the international
ISO color-coding system. This is because of a number of
limitations including the existence of more look-alike drugs or
drug groups than there are colors that could be used in the ISO
color-coding system, and the prevalence of congenital color vi-
sion deficiency which affects about 8% of men and 0.4% of
women in the general population [18]. Despite these limitations,
more importantly, evidence suggests that healthcare profes-
sionals will rely solely on the color of the labels, and not read
the labels at all [19, 20]. Remarkably, many hospital pharmacists
in Germany and the UKwere not aware (based on the comments
as free text in the survey) of the possibility of using “Tall Man”
lettering and pictograms as a label-enhancement method.
One of the main limitations of this survey is the low response
rate of the survey in Germany and the UK. Despite the reminder
emails that were sent, the response rate remained low.
Our findings give valuable insights into the labeling practices
of hospital pharmacy production units in the Netherlands,
Germany, and the UK and this is the basis for further work.
Our results suggest that a first step is creating more awareness
Fig. 1 Examples of labels using Tall Man lettering, data matrix, and barcoding
Table 1 Results survey




The UK (n =
15)
n % n % n %
Overall response rate 48 63.2 41 10.5 15 #
Hospital type
Local 28 58.3 7 17.1 8 53.3
Tertiary hospital 16 33.3 11 26.8 7 46.7
Academic 4 8.3 17 41.5 0
Other 3 7.3
Production facility pharmacy 31 64.6 36 87.8 15 100.0
Applying national guideline for labeling* 26 83.9 33 91.7 14 93.3
Using color coding 5 16.1 18 50.0 3 20.0
Using Tall Man lettering 5 16.1 5 13.9 4 26.7
Using pictograms/icons 2 6.5 0 0 0 0
Using barcoding/data matrix code 17 54.8 2 5.6 3 20.0
Warning signs epidural medication 4 12.9 24 66.7 10 66.7
Warning sign multiple doses 11 35.5 15 41.7 4 26.7
#No percentage could be calculated because it was unknown how many pharmacists received the survey
*National labeling guidelines: the Netherlands: guideline labeling Dutch Association of Hospital Pharmacists
(2011); Germany: Apothekenbetriebsordnung (ApBetrO § 14); the UK: “Best practice guidance on labelling and
packaging of medicines” from the MHRA and “Medicines, Ethics and Practice - The Professional Guide for
Pharmacists” from the Royal Pharmaceutical Society
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among European hospital pharmacists about the different
methods of label enhancements. In light of the variety of ap-
proaches utilized and lack of specificity in national guidelines,
more research is urgently needed to strengthen the evidence base
on safe labeling methods in order to guide practice [10]. Such
research needs to be approached from a practice-perspective, as
labeling is only one aspect of a multifaceted approach to improve
safe medication use in hospitals including procedures such as
double checking [21, 22] or safe preparation of aseptic products
[23]. Also the use of computerized decision support in combina-
tion with a barcode on the label may further decrease the risk of
medication errors. In a survey in 2017 of the European
Associations of Hospital Pharmacists, 45% of the respondents
reported use of computerized decision support, with high varia-
tion between countries. For example, 90% of the respondents in
the Netherlands used decision support, whereas less than 40% in
the UK did so [1]. Multicenter studies are needed to evaluate the
impact of interventions in practice settings as shown in a recent
study completed in the USA, evaluating the impact of intro-
ducing “Tall Man” lettering on prescription errors [24].
Collaborations across European countries could be very useful
to drive this agenda forward. Eventually, standardization across
Europe should improve safety, as using different color-coding
systems, could create confusion and compromise patient safety.
A European guideline summarizing current evidence and best
practices could be a first step in achieving this goal.
Conclusion
Our study in the Netherlands, Germany, and the UK suggests
that label-enhancement methods for parenteral medication in
hospital pharmacies are not widely implemented and ac-
knowledged in hospitals in these countries. Hospitals use na-
tional guidelines but also various locally developed methods
for label enhancement. A larger-scale survey with a better
response rate would be needed to confirm if this a
European-wide issue. Greater standardization in conjunction
with research for evidence-based enhancement techniques is
needed to guide improvement in labeling practices.
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Fig. 2 Overview of the color-coding scheme developed by the German
Interdisciplinary Association for Intensive Care and EmergencyMedicine
(Deutsche Interdisziplinäre Vereinigung für Intensiv- und
Notfallmedizin, DIVI) [15]
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